Evaluation of influenza virus antiviral susceptibility testing in Europe: results from the first external quality assessment exercise.

[1]  Maria Zambon,et al.  Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. , 2012, The Lancet. Infectious diseases.

[2]  A. Kelso,et al.  Community transmission of oseltamivir-resistant A(H1N1)pdm09 influenza. , 2011, The New England journal of medicine.

[3]  R. Pebody,et al.  Oseltamivir-Resistant Pandemic (H1N1) 2009 Virus Infection in England and Scotland, 2009–2010 , 2011, Emerging infectious diseases.

[4]  Ha T. Nguyen,et al.  Comprehensive assessment of 2009 Pandemic Influenza a (H1N1) Virus Drug Susceptibility in vitro , 2010, Antiviral therapy.

[5]  M. Koopmans,et al.  Influenza Virus Inactivation for Studies of Antigenicity and Phenotypic Neuraminidase Inhibitor Resistance Profiling , 2010, Journal of Clinical Microbiology.

[6]  J. van de Kassteele,et al.  Oseltamivir-Resistant Influenza Virus A (H1N1), Europe, 2007–08 Season , 2009, Emerging infectious diseases.

[7]  A. Lackenby,et al.  The potential impact of neuraminidase inhibitor resistant influenza , 2008, Current opinion in infectious diseases.

[8]  M. Zambon,et al.  Rapid Quantitation of Neuraminidase Inhibitor Drug Resistance in Influenza virus Quasispecies , 2008, Antiviral therapy.

[9]  M. Zambon,et al.  Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. , 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[10]  N. Cox,et al.  Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. , 2007, The Journal of infectious diseases.

[11]  M. Zambon,et al.  Influenza antiviral susceptibility monitoring activities in relation to national antiviral stockpiles in Europe during the winter 2006/2007 season. , 2007, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[12]  M. Kiso,et al.  Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  M. Zambon,et al.  Programme of the Community Network of Reference Laboratories for Human Influenza to improve Influenza Surveillance in Europe. , 2006, Vaccine.

[14]  J. Paget,et al.  Implementation of the community network of reference laboratories for human influenza in Europe. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[15]  Xiyan Xu,et al.  Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern , 2005, The Lancet.

[16]  F. Hayden,et al.  Neuraminidase Sequence Analysis and Susceptibilities of Influenza Virus Clinical Isolates to Zanamivir and Oseltamivir , 2003, Antimicrobial Agents and Chemotherapy.

[17]  M. Valette,et al.  Quality control assessment of influenza and RSV testing in Europe: 2000-01 season. , 2002, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[18]  D. Lavanchy,et al.  Influenza and the work of the World Health Organization. , 2002, Vaccine.

[19]  F. Hayden,et al.  Position statement: global neuraminidase inhibitor susceptibility network. , 2001, Antiviral research.

[20]  R. Bethell,et al.  Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir. , 2000, Analytical biochemistry.

[21]  M. Potier,et al.  Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate. , 1979, Analytical biochemistry.